Please use this identifier to cite or link to this item:
Title: Brexit : the pharma industry and Malta’s availability of medicines
Other Titles: Brexit : the pharma industry and Malta’s availability of medicines
Editorial [The Synapse, 15(2)] 
Authors: Ellul, Ian C.
Keywords: Pharmaceutical industry -- Malta
European Union -- History -- 21st century
Great Britain -- Foreign relations -- European Union countries
European Union -- Great Britain
Great Britain -- Politics and government -- 1997-
Pharmaceutical industry -- Great Britain
Drugs -- Malta
Issue Date: 2016
Publisher: Medical Portals Ltd.
Citation: Ellul, Ian, C. (2016). Brexit : the pharma industry & Malta’s availability of medicines. The Synapse, 15(2), 3
Abstract: Editorial about the referendum date when British, Irish and Commonwealth citizens will decide whether the UK will withdrawal from the EU or not. A possible Brexit would undoubtedly impinge on the healthcare sector. Another concern relates to the issue of patents, including pharmaceutical ones. Reference to the European Medicines Agency which is the regulatory body responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU, and what would happen if a Brexit materialises. Another aspect is that Malta has over 1400 medicines licensed in Malta which are sourced from the UK market through various European procedures.
Appears in Collections:The Synapse, Volume 15, Issue 2
The Synapse, Volume 15, Issue 2

Files in This Item:
File Description SizeFormat 
Brexit - editorial.pdf128.59 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.